U.S. biotechnology firm Moderna Inc. said Wednesday new clinical data on an experimental coronavirus vaccine showed effectiveness against the Omicron variant, making it the company's lead candidate for distribution as a fall booster shot.According to the data, a booster dose of the latest vaccine increased Omicron-fighting antibodies approximately eight-fold, one month after its administration, when compared to the original version."We anticipate more durable protection against variants of concern," Moderna CEO Stephane Bancel said in a press release, noting the company will be submitting t…READ FULL ARTICLE
